Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 10, 2021 08:30 ET | Source: Chiesi USA, Inc.

Chiesi Group calls for #ActionOverWords in the fight against climate change

Chiesi Group, the largest international pharmaceutical company Certified B Corporation™, reinforces 2035 carbon neutral target with #ActionOverWords campaign to encourage measurable sustainability...
April 21, 2021 09:00 ET | Source: Chiesi USA, Inc.

Chiesi Group receives European Marketing Authorization for Trimbow® inhalation powder (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium) delivered through NEXThaler, an extrafine formulation fixed triple combination therapy for the treatment of moderate to severe COPD

Chronic obstructive pulmonary disease (COPD) patients for whom a dry powder inhaler device is preferred, can now benefit from an extrafine formulation fixed triple combination therapy containing an...
March 29, 2021 09:00 ET | Source: Chiesi USA, Inc.

Chiesi USA Appoints VP of Medical Affairs to Support Continued Growth

CARY, N.C., March 29, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), has...
March 22, 2021 09:00 ET | Source: Chiesi USA, Inc.

Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences

New visual identity is the first public manifestation of Chiesi Group’s continued transformation as a Certified B Corporation™ businessPatients’ experiences and perception of Chiesi at the heart of...
March 18, 2021 09:00 ET | Source: Chiesi USA, Inc.

Chiesi Group announces performance growth in 2020

Chiesi Group currently employs 6,389 people worldwide, 2,119 of whom are in Italy, and has a turnover of €2.229 billion.Chiesi’s business comprises 30 affiliates, seven research centers, three...
March 17, 2021 09:00 ET | Source: Chiesi USA, Inc.

Chiesi USA, Inc. announces Commercial Availability of Bronchitol® (mannitol) inhalation powder for improvement in pulmonary function in adult patients with cystic fibrosis

CARY, N.C., March 17, 2021 (GLOBE NEWSWIRE) -- Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced the...
March 16, 2021 09:00 ET | Source: Chiesi USA, Inc.

Chiesi USA Announces Sponsorship of ASHP Foundation’s Pharmacy Leadership Scholars Program

CARY, N.C., March 16, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced...
March 01, 2021 09:00 ET | Source: Chiesi USA, Inc.

Chiesi USA donates more than $800,000 in 2020

CARY, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group),...
February 01, 2021 09:00 ET | Source: Chiesi USA, Inc.

Chiesi Group receives the European Marketing authorization for the extrafine triple-combination therapy for the treatment of moderate to severe asthma

It is the first extrafine fixed triple combination therapy in a single inhaler to be approved for use in asthma patients. This follows the 2017 approval of this therapeutic option for the treatment of...
January 25, 2021 09:30 ET | Source: Chiesi USA, Inc.

Chiesi USA, Inc. Receives Top Employer in the U.S. Certification for 2021

CARY, N.C., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right